While 2017 was a banner year, it was also highly speculative; subsequent years saw many of these same stocks lose significant value as the "hype" met the reality of post-legalization logistics.
Moved to the larger TSX exchange and entered the German market
: A unique feature of 2017 was the divergence between markets. While Canadian licensed producers (LPs) like Aphria and Village Farms flourished under a clear path to federal legalization, U.S.-based stocks remained largely stagnant due to federal prohibition and legal uncertainty. Notable Performers of 2017 Stock Name 2017 Performance (Approx.) Key Driver Aurora Cannabis (ACB)
Growth in Canadian medical sales and preparation for adult-use Partnership with Constellation Brands InMed Pharmaceuticals Research into cannabinoid-based therapies